Clomipramine

Lore & Background

It is on the World Health Organization's List of Essential Medicines and is available as a generic medication. Its mechanism of action is not entirely clear but is believed to involve increased levels of serotonin and norepinephrine. It is typically taken by mouth, although intravenous preparations are sometimes used.

Reader's Guide

Clomipramine is a tricyclic antidepressant with a broad range of medical uses, most notably for obsessive–compulsive disorder (OCD), for which it is the only US FDA-labeled indication. It is also approved by other regulatory agencies for OCD and for major depressive disorder, panic disorder, and cataplexy associated with narcolepsy. Despite its efficacy, clomipramine is often a second-line choice due to a potentially greater side-effect profile compared to SSRIs. Common side effects include dry mouth, constipation, loss of appetite, sleepiness, weight gain, sexual dysfunction, and trouble urinating. Serious side effects include increased risk of suicidal behavior in those under 25, seizures, mania, and liver problems. Withdrawal syndrome may occur if stopped suddenly. Its use during pregnancy is associated with congenital heart defects, and it is distributed in breast milk, so nursing is advised against.

Did You Know?

• It is on the World Health Organization's List of Essential Medicines.
• Clomipramine may paradoxically increase the risk of suicide in those under the age of 25, at least in the first few weeks of treatment.

Identity and Pharmacological Home

Anafranil is the trade name under which clomipramine reaches patients, and its pharmacological identity is clear: it belongs to the tricyclic antidepressant family. In a field where brand names often obscure the chemistry beneath, Anafranil stands as a recognizable label for a molecule whose structural classification places it firmly among the tricyclics. This is not a minor detail. The tricyclic grouping carries its own pharmacological heritage, distinguishing these agents from the selective serotonin reuptake inhibitors, the serotonin-norepinephrine reuptake inhibitors, the atypical antidepressants, and the host of other classes that populate modern psychiatric formularies. Clomipramine, then, is not an outlier or an experimental compound; it is a well-defined member of a class that has been a mainstay of mood and anxiety pharmacology for decades. Its presence in the alphabetized roster of marketed psychotropics, listed under the letter A for Anafranil, underscores that it remains an active, commercially available option rather than a historical footnote.

The Obsessive-Compulsive Focus

Among the many indications that psychotropic drugs can carry, clomipramine's profile is strikingly focused. The reference material describes it as mostly used to treat obsessive-compulsive disorder, a designation that sets it apart from the broader, more diffuse uses of its tricyclic peers. Where amitriptyline is highlighted as a first-line treatment for neuropathic pain, or doxepin is noted for nerve pain and insomnia, clomipramine's primary therapeutic identity is anchored in OCD. This is not to say it is a narrow tool in every possible sense, but the emphasis in the available description points squarely toward compulsive and obsessive symptomatology as the condition it is most associated with. In a pharmacological landscape where SSRIs like fluoxetine, paroxetine, and escitalopram are listed as antidepressants, and SNRIs like venlafaxine and duloxetine occupy their own category, clomipramine's tricyclic identity combined with its OCD-centric role gives it a distinctive niche. It is the tricyclic that clinicians reach for when the diagnosis is obsessive-compulsive disorder, a role that distinguishes it from the antidepressant tricyclics that lean more toward pain management or sleep.

The Tricyclic Family Table

Clomipramine does not sit alone in the tricyclic antidepressant category. The same reference list that places Anafranil under the letter A also catalogs several fellow tricyclics, each with its own brand names and therapeutic leanings. Doxepin, marketed as Aponal, Quitaxon, or Sinequan, is described as similar to imipramine and used for nerve pain and insomnia. Amitriptyline, known as Elavil, is positioned as a first-line treatment for neuropathic pain. Nortriptyline carries the brand Pamelor, and desipramine appears under the name Norapramin with a noted role in nerve pain treatment. This constellation of tricyclics reveals a family with diverse applications: some lean toward pain, some toward sleep, and clomipramine toward obsessive-compulsive symptoms. The shared structural classification unites them, yet their individual therapeutic profiles diverge. For a reader trying to understand where clomipramine fits, the tricyclic family table provides essential context. It is one voice in a chorus of related molecules, each tuned to a different clinical frequency, all sharing the same three-ring chemical architecture that defines their class.

A Complete Roster, One Letter A

This framing matters. It means Anafranil is not a withdrawn or experimental drug; it occupies a confirmed slot in the active pharmaceutical landscape alongside hundreds of other agents. The list stretches from Abilify and Adderall at the top of the A section through Buspar and Belsomra in the B section, past Celexa and Clozaril in the C section, and onward through dozens of additional letters. Within this vast roster, clomipramine shares its A-section neighborhood with aripiprazole, mixed amphetamine salts, zolpidem, disulfiram, doxepin, benperidol, donepezil, lorazepam, amoxapine, and serdexmethylphenidate/dexmethylphenidate. The sheer breadth of the list, from atypical antipsychotics to stimulants, from sleep aids to anti-anxiety agents, from mood stabilizers to anticonvulsants, underscores the complexity of modern psychiatric pharmacology. Clomipramine's place in this complete, current roster affirms its continuing relevance as a marketed, accessible treatment option in a field that spans an enormous range of conditions and chemical strategies.